Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)

Market Cap	3.92B -36.6%
Revenue (ttm)	852.85M +266.9%
Net Income	592.98M
EPS	0.77
Shares Out	782.28M
PE Ratio	6.55
Forward PE	15.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,242,000
Open	5.28
Previous Close	5.38
Day's Range	4.96 - 5.28
52-Week Range	3.98 - 9.29
Beta	0.35
Analysts	Buy
Price Target	9.83 (+96.01%)
Est. Earnings	Nov 24, 2026

About HKG:1167

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People’s Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic mal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 207
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1167

Financial Performance

In 2025, HKG:1167's revenue was 53.53 million, a decrease of -65.62% compared to the previous year's 155.71 million. Losses were -145.98 million, -6.25% less than in 2024.

Financial numbers in CNY

Analyst Summary

According to 2 analysts, the average rating for 1167 stock is "Buy." The 12-month stock price target is $9.83, which is an increase of 96.01% from the latest price.

Price Target

$9.83

(96.01% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error